Complex Generics: US FDA, Sponsors View Roadblocks Very Differently
Executive Summary
As GDUFA III negotiations continue, FDA doesn’t seem ready to make additional changes to approval process, but industry argues guidance practices and communications need fixing and that consumers are missing out on potential savings because of it.
You may also be interested in...
GDUFA III Talks Completed
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.
GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.
US GDUFA III Talks In Final Stages, Agreement Nearly Complete
Final commitment letter preparations now under way as revenue issues are resolved.